Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $57.10

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average recommendation of “Buy” from the eleven analysts that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $57.10.

Several research analysts have weighed in on the company. Leerink Partners increased their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Robert W. Baird raised their price target on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Finally, Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th.

Insider Buying and Selling

In other news, CEO Christopher Peetz sold 7,489 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Peter Radovich sold 1,998 shares of the firm’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total value of $85,554.36. Following the sale, the chief operating officer now directly owns 27,015 shares in the company, valued at approximately $1,156,782.30. This trade represents a 6.89 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,415 shares of company stock worth $2,015,670. Corporate insiders own 22.87% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its position in Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after purchasing an additional 318 shares during the last quarter. R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals during the fourth quarter worth about $69,000. Avanza Fonder AB bought a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000. ProShare Advisors LLC acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $213,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter valued at $215,000.

Mirum Pharmaceuticals Stock Up 4.1 %

MIRM stock opened at $52.28 on Monday. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The business has a 50 day moving average price of $44.49 and a two-hundred day moving average price of $42.10. Mirum Pharmaceuticals has a twelve month low of $23.14 and a twelve month high of $53.49. The company has a market cap of $2.51 billion, a price-to-earnings ratio of -25.88 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s quarterly revenue was up 89.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.57) EPS. Analysts anticipate that Mirum Pharmaceuticals will post -1.44 EPS for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.